25 August 2025
In the rapidly evolving landscape of cell therapy, particularly with the rise of allogeneic (“off-the-shelf”) CAR-T treatments, agility and expertise are no longer optional—they are essential. Traditional large CROs, while proven at scale, often fall short when it comes to the nuanced, high-stakes demands of pioneering therapies that are redefining medicine. That’s where CRO flexibility...